Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ayala Pharmaceuticals, Inc. (ADXS : OTC)

• Company Description    Ayala Pharmaceuticals Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. It also involved in developing proprietary Lm-based antigen delivery products for patients suffering from more common cancers. The company's lead candidates under development are AL102 and ADXS-504. Ayala Pharmaceuticals Inc., formerly known as Advaxis Inc., is based in REHOVOT, Israel. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $0.03 Daily Weekly Monthly 20 Day Moving Average: 560 shares Shares Outstanding: 42.63 (millions) Market Capitalization: $1.42 (millions) Beta: 1.17 52 Week High: $0.22 52 Week Low: $0.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -4.34% 12 Week 11.00% -9.44% Year To Date 23.33% 16.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9 DEER PARK DRIVE SUITE K-1 - MONMOUTH JUNCTION,NJ 08852 USA ph: 609-452-9813 fax: 609-452-9818 ir@ayalapharma.com http://www.ayalapharma.com

• General Corporate Information    Officers Kenneth Berlin - President; Chief Executive Officer and Director David Sidransky - Chairman Vered Bisker-Leib - Vice Chairman Roy Golan - Chief Financial Officer Roni A. Appel - Director Peer Information Ayala Pharmaceuticals, Inc. (GSAC) Ayala Pharmaceuticals, Inc. (CASI) Ayala Pharmaceuticals, Inc. (ALCD.) Ayala Pharmaceuticals, Inc. (OMNN) Ayala Pharmaceuticals, Inc. (CGPI.) Ayala Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 007624406 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 42.63 Most Recent Split Date: 6.00 (0.01:1) Beta: 1.17 Market Capitalization: $1.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©